BOLT Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Bolt Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.57 |
| 52 Week High | US$1.56 |
| 52 Week Low | US$0.54 |
| Beta | 0.92 |
| 11 Month Change | -14.12% |
| 3 Month Change | -17.57% |
| 1 Year Change | -36.95% |
| 33 Year Change | -93.77% |
| 5 Year Change | n/a |
| Change since IPO | -98.24% |
Recent News & Updates
Recent updates
Little Excitement Around Bolt Biotherapeutics, Inc.'s (NASDAQ:BOLT) Revenues As Shares Take 29% Pounding
May 21
We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully
Mar 15Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?
May 13Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?
Dec 01Bolt Biotherapeutics: A Promised Follow Up
Aug 26Bolt Biotherapeutics GAAP EPS of -$0.61 beats by $0.08, revenue of $1.39M beats by $0.89M
Aug 10We're Keeping An Eye On Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate
Jul 27We're Not Very Worried About Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate
Apr 12We Think Bolt Biotherapeutics (NASDAQ:BOLT) Can Afford To Drive Business Growth
Dec 03Bolt Biotherapeutics: Pioneering A New Class Of Immunotherapies
Aug 18We're Hopeful That Bolt Biotherapeutics (NASDAQ:BOLT) Will Use Its Cash Wisely
Aug 18Shareholder Returns
| BOLT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.9% | -3.7% | 0.3% |
| 1Y | -37.0% | 15.2% | 31.1% |
Return vs Industry: BOLT underperformed the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: BOLT underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| BOLT volatility | |
|---|---|
| BOLT Average Weekly Movement | 5.5% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BOLT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BOLT's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 100 | Willie Quinn | www.boltbio.com |
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer.
Bolt Biotherapeutics, Inc. Fundamentals Summary
| BOLT fundamental statistics | |
|---|---|
| Market cap | US$21.81m |
| Earnings (TTM) | -US$65.08m |
| Revenue (TTM) | US$9.78m |
2.2x
P/S Ratio-0.3x
P/E RatioIs BOLT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BOLT income statement (TTM) | |
|---|---|
| Revenue | US$9.78m |
| Cost of Revenue | US$61.54m |
| Gross Profit | -US$51.76m |
| Other Expenses | US$13.32m |
| Earnings | -US$65.08m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.70 |
| Gross Margin | -529.33% |
| Net Profit Margin | -665.56% |
| Debt/Equity Ratio | 0% |
How did BOLT perform over the long term?
See historical performance and comparison